Draft:Paola Marignani
Review waiting, please be patient.
This may take 4 months or more, since drafts are reviewed in no specific order. There are 2,844 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Paola A. Marignani | |
---|---|
Nationality | Canadian |
Alma mater | University of Windsor (H BSc) University of Western Ontario (MSc) McMaster University (PhD) Harvard (Postdoctoral Fellow) Ivey School of Business (EMBA) |
Scientific career | |
Fields | Molecular Biology, Precision Medicine, Single-cell transcriptomics |
Institutions | Dalhousie University |
Website | https://marignanilab.com/ |
Paola A. Marignani is a scientist and Full Professor at Dalhousie University in the Faculty of Medicine, Department of Biochemistry and Molecular Biology.[1] She is best known for her research on the tumor suppressor kinase LKB1,[2] and its role in regulating the chromatin remodeling protein SMARCA4 and modeling metabolic processes in breast and lung cancers. [3][4][5]
Biography[edit]
Marignani completed her Hon BSc in Biology from the University of Windsor, followed by an MSc in Neurobiology from the University of Western Ontario.[1] She earned her PhD in Cell Biology from McMaster University. Her postdoctoral training took place at Harvard Medical School in the Division of Signal Transduction followed by the Lunenfeld-Tanenbaum Research Institute and the Ontario Cancer Institute in Toronto, Ontario. She also holds an Executive MBA from the Ivey School of Business at Western University, and a Certificate from MIT Sloan School of Management in Artificial Intelligence in Health Care.[6]
Scientific Career[edit]
The primary focus of Marignani’s research program is tumor suppressors.[7] Marignani combines technologies such as single-cell transcriptomics and machine learning[8] to interrogate disease processes within the framework of precision medicine discovery pipelines.[9][6][10][11]
Marignani’s early research focused on understanding the molecular changes to signaling molecules resulting from polyunsaturated fatty acid incorporation into lipid membranes. She discovered that the integration of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) into lipid membranes altered diacylglycerol profiles in murine macrophages, which could lead to downstream changes in signaling events.[12]
Marignani is involved in promoting diversity and inclusion in STEM fields. She is the Founder of Canadian Women in STEM, an organization aimed at building a national strategy for equity, diversity, and inclusion in Canada, and provides an accessible network that enables ease of communication among women in STEM.[8]
Selected Publications[edit]
- Jinhong Kim; Paola A. Marignani (2022). "Single-Cell RNA Sequencing Analysis Using Fluidigm C1 Platform for Characterization of Heterogeneous Transcriptomes". Methods in Molecular Biology: 261–278. doi:10.1007/978-1-0716-2376-3_19. ISSN 1064-3745. Wikidata Q125798347.
- Jinhong Kim; Zhaolin Xu; Paola A Marignani (15 October 2021). "Single-cell RNA sequencing for the identification of early-stage lung cancer biomarkers from circulating blood". NPJ genomic medicine. 6 (1): 87. doi:10.1038/S41525-021-00248-Y. ISSN 2056-7944. PMC 8519939. PMID 34654834. Wikidata Q112643227.
- Ava Vila-Leahey; Sharon A Oldford; Paola A Marignani; Jun Wang; Ian D Haidl; Jean S Marshall (10 March 2016). "Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice". OncoImmunology. 5 (7): e1151591. doi:10.1080/2162402X.2016.1151591. ISSN 2162-4011. PMC 5006904. PMID 27622015. Wikidata Q37222105.
- Rafaela Andrade-Vieira; Donna Goguen; Heidi A Bentley; Chris V Bowen; Paola A Marignani (1 December 2014). "Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss". Oncotarget. 5 (24): 12738–12752. doi:10.18632/ONCOTARGET.2818. ISSN 1949-2553. PMC 4350354. PMID 25436981. Wikidata Q35149656.
- Rafaela Andrade-Vieira; Zhaolin Xu; Patricia Colp; Paola A Marignani (22 February 2013). "Loss of LKB1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways". PLOS One. 8 (2): e56567. Bibcode:2013PLoSO...856567A. doi:10.1371/JOURNAL.PONE.0056567. ISSN 1932-6203. PMC 3579833. PMID 23451056. Wikidata Q34602408.
- Suchita Nath-Sain; Paola A Marignani (15 April 2009). "LKB1 catalytic activity contributes to estrogen receptor alpha signaling". Molecular Biology of the Cell. 20 (11): 2785–2795. doi:10.1091/MBC.E08-11-1138. ISSN 1059-1524. PMC 2688557. PMID 19369417. Wikidata Q37207745.
- Kristine D Scott; Suchita Nath-Sain; Meghan D Agnew; Paola A Marignani (1 June 2007). "LKB1 catalytically deficient mutants enhance cyclin D1 expression". Cancer Research. 67 (12): 5622–5627. doi:10.1158/0008-5472.CAN-07-0762. ISSN 0008-5472. PMID 17575127. Wikidata Q53545879.
- P A Marignani; F Kanai; C L Carpenter (31 August 2001). "LKB1 associates with Brg1 and is necessary for Brg1-induced growth arrest". Journal of Biological Chemistry. 276 (35): 32415–8. doi:10.1074/JBC.C100207200. ISSN 0021-9258. PMID 11445556. Wikidata Q28205561.
- P A Marignani; C L Carpenter (9 July 2001). "Vav2 is required for cell spreading". Journal of Cell Biology. 154 (1): 177–86. doi:10.1083/JCB.200103134. ISSN 0021-9525. PMC 2196856. PMID 11448999. Wikidata Q24654126.
- F Kanai; P A Marignani; D Sarbassova; et al. (15 December 2000). "TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins". The EMBO Journal. 19 (24): 6778–91. doi:10.1093/EMBOJ/19.24.6778. ISSN 0261-4189. PMC 305881. PMID 11118213. Wikidata Q24290626.
References[edit]
- ^ a b "Marignani, P. A." Dalhousie University. Retrieved 2024-05-12.
- ^ Andrade-Vieira, Rafaela; Goguen, Donna; Bentley, Heidi A.; Bowen, Chris V.; Marignani, Paola A. (2014-12-30). "Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss". Oncotarget. 5 (24): 12738–12752. doi:10.18632/oncotarget.2818. ISSN 1949-2553. PMC 4350354. PMID 25436981.
- ^ Marignani, Paola A.; Kanai, Fumihiko; Carpenter, Christopher L. (2001-08-31). "LKB1 Associates with Brg1 and Is Necessary for Brg1-induced Growth Arrest". Journal of Biological Chemistry. 276 (35): 32415–32418. doi:10.1074/jbc.C100207200. PMID 11445556.
- ^ "Nova Scotia breast cancer researcher receives $250K grant". Atlantic. 2022-07-18. Retrieved 2024-05-12.
- ^ International, Radio Canada (2014-12-15). "Exciting Canadian advance against breast cancer". RCI | English. Retrieved 2024-05-13.
- ^ a b "$250,000 Grant to Dr. Paola Marignani to identify HER2+ markers". Breast Cancer Canada. 2022-06-15. Retrieved 2024-05-12.
- ^ "Turning off the power: Dr. Paola Marignani finds drug combination that stops growth of breast cancer cells". Dalhousie University. Retrieved 2024-05-12.
- ^ a b Jussinoja, Kaija. "Meet the local scientist changing the narrative for cancer". The Coast Halifax. Retrieved 2024-05-12.
- ^ "LKB1 Tumour Suppressor kinase". Marignani Discovery Research Laboratory. 2017-07-24. Retrieved 2024-05-12.
- ^ Kim, Jinhong; Xu, Zhaolin; Marignani, Paola A. (2021-10-15). "Single-cell RNA sequencing for the identification of early-stage lung cancer biomarkers from circulating blood". npj Genomic Medicine. 6 (1): 87. doi:10.1038/s41525-021-00248-y. ISSN 2056-7944. PMC 8519939. PMID 34654834.
- ^ Kim, Jinhong; Marignani, Paola A. (2022), Christian, Sherri L. (ed.), "Single-Cell RNA Sequencing Analysis Using Fluidigm C1 Platform for Characterization of Heterogeneous Transcriptomes", Cancer Cell Biology, vol. 2508, New York, NY: Springer US, pp. 261–278, doi:10.1007/978-1-0716-2376-3_19, ISBN 978-1-0716-2375-6, PMID 35737246, retrieved 2024-05-12
- ^ Marignani, Paola A.; Epand, Richard M.; Sebaldt, Rolf J. (1996-08-14). "Acyl Chain Dependence of Diacylglycerol Activation of Protein Kinase C Activity in vitro". Biochemical and Biophysical Research Communications. 225 (2): 469–473. doi:10.1006/bbrc.1996.1196. PMID 8753785.
Category:Canadian molecular biologists Category:Canadian women scientists Category:21st-century Canadian scientists Category:20th-century Canadian scientists Category:21st-century Canadian women scientists Category:20th-century Canadian women scientists Category:Academic staff of Dalhousie University